ES 
EN 
DE 
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
The anti-obesity pharmacology of the past decade has revolved around a design question: what should be added to GLP-1 agonism to achieve an additive or synergistic effect in body weight reduction? CagriSema and tirzepatide represent two different answers. CagriSema (Novo Nordisk) adds a second peptide — an amylin analogue (cagrilintide). Tirzepatide (Eli Lilly) adds a second receptor within the same molecule (GIPR). This article compares the mechanisms, molecular architectures and results of the published studies — without suggesting which peptide “wins”. The comparison is indirect: different studies, populations and phases.
CagriSema (semaglutide + cagrilintide) and tirzepatide are two different strategies for enhancing the action of GLP-1 — CagriSema adds amylin activity, tirzepatide adds GIP activity. Tirzepatide is an approved medicine (Mounjaro in T2D, Zepbound in obesity); CagriSema remains in the phase III REDEFINE programme.
Regulatory box — a critical distinction
The two molecules operate under different legal statuses:
- Tirzepatide — an approved medicine (FDA: Mounjaro 2022 in T2D, Zepbound 2023 in obesity; EMA: Mounjaro 2022 in T2D and obesity). Requires a medical prescription.
- CagriSema — a combination of pharmaceutical candidates in phase III (REDEFINE, Novo Nordisk). It is not an approved medicine.
- In the One Peptides catalogue, both peptides function as research reagents (Research Use Only) — with no protocols for human use.
The common denominator of the two molecules is activity at the GLP-1 receptor: increased insulin secretion after a meal, reduced appetite through central signalling, and slowed gastric emptying. The difference lies in what was added alongside GLP-1 and how it was added architecturally.
The informal shorthand used for retatrutide in online searches is explained in a separate entry: the informal name “reta”.
CagriSema is a combination of two separate molecules, administered in a single solution, in one subcutaneous injection, once a week:
Both peptides have a compatible half-life (~7 days) thanks to structural modifications (fatty-acid acylation, stabilising substitutions). Novo Nordisk is developing CagriSema as a fixed-dose combination drug. Available in the One Peptides catalogue as Sema+Cagri PEN 2mg+2mg.
Tirzepatide (Eli Lilly internal designation: LY3298176) is a single molecule with a sequence of 39 amino acids, activating two receptors at once — GLP-1R and GIPR. The sequence is based on native GIP, with modifications for affinity to GLP-1R, acylation with a C20 fatty-acid chain and a half-life of ~5 days. Available in the catalogue as GLP-1+GIP 5mg PEN.
An important difference: in CagriSema the ratio of GLP-1:amylin activity can be adjusted by dosing the two peptides separately; in tirzepatide the ratio of GLP-1R:GIPR activity is built into the molecule and is not subject to separate adjustment.
The GLP-1 receptor is located in the pancreas, the CNS, the heart, the kidneys and the gastrointestinal tract. Activation produces an increase in glucose-dependent insulin secretion, a reduction in glucagon secretion, slowed gastric emptying and central satiety signalling. A full overview of the incretin axis is given in the article on incretins GLP-1, GIP and glucagon.
Cagrilintide activates the amylin receptor (AMY) — a complex of the calcitonin receptor with the modulating protein RAMP. The main satiety mechanism proceeds through the area postrema — a structure in the brainstem outside the blood–brain barrier. Activation of the amylin receptor in this region generates a satiety signal that is independent of the GLP-1 axis.
Tirzepatide activates the GIP receptor. GIP is the second — alongside GLP-1 — major incretin hormone from the gut. Activation of GIPR by tirzepatide results in a synergistic increase in glucose-dependent insulin secretion, modulation of adipose tissue metabolism and an effect on central satiety circuits.
Amylin and GIP act on different tissues and circuits, leading to a similar clinical effect by different routes. CagriSema adds a satiety signal through the area postrema; tirzepatide adds a second incretin hormone in the pancreas and metabolic circuits.
A direct juxtaposition of the figures from the CagriSema and tirzepatide studies is NOT a head-to-head comparison. Methodological differences: different populations, observation periods, dosing schedules, endpoints and sponsors. No RCT directly comparing CagriSema with tirzepatide has been published in the literature. Any numerical juxtapositions are an indirect comparison.
| Characteristic | CagriSema | Tirzepatide |
|---|---|---|
| Architecture | Combo of two peptides (fixed-dose) | Single-molecule dual agonist |
| Molecules | Semaglutide + cagrilintide | LY3298176 (39 aa) |
| Receptors | GLP-1R + AMY (amylin) | GLP-1R + GIPR |
| Second pathway | Amylin — satiety through the area postrema | GIP — synergistic incretin effect |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Regulatory status (2026) | Phase III REDEFINE — not approved | Approved medicine — Mounjaro, Zepbound |
| Half-life | ~7 days (both peptides) | ~5 days |
| Main studies | Lau 2021 Lancet, Enebo 2021 Lancet | Jastreboff 2022 SURMOUNT-1, Frias 2021 SURPASS-2 |
| Weight reduction (published) | Early phase 2/3 data — high values | ~22.5% in the 15 mg group (SURMOUNT-1, 72 weeks) |
| Adverse effects | Gastrointestinal + amylinergic | Predominantly gastrointestinal (nausea 25–31%) |
| Separate adjustment of components | Yes — doses adjustable separately | No — ratio built into the molecule |
CagriSema. Early data (Enebo 2021, Lau 2021) suggest a high body weight reduction with preserved tolerability. The addition of cagrilintide introduces a profile of amylinergic effects — nausea typical of AMY activation — overlapping with the GLP-1 profile. The full phase III REDEFINE data have not yet been published (as of 2026).
Tirzepatide. The SURMOUNT and SURPASS data cover tens of thousands of participants in phase III. The safety profile is well characterised. FDA and EMA approval means that the risk–benefit profile has been assessed by the regulators.
No head-to-head. No RCT directly comparing the two molecules has been published.
The fundamental difference is the second receptor alongside GLP-1. CagriSema activates GLP-1R and the amylin receptor (AMY) through a combination of two separate peptides. Tirzepatide activates GLP-1R and GIPR through a single molecule of 39 aa. The molecular architecture and the satiety circuits are different.
The answer requires caution. Tirzepatide 15 mg in SURMOUNT-1 produced a reduction of ~22.5% over 72 weeks. Early REDEFINE data for CagriSema report values in a similar or higher range, but in different populations and protocols. The absence of a head-to-head RCT makes a clinically reliable conclusion impossible.
Amylin (a hormone of the pancreatic β cells) signals central satiety through the AMY receptor in the area postrema. GIP (an incretin hormone from the gut) enhances insulin secretion and modulates adipose tissue metabolism.
No. CagriSema remains in phase III clinical trials (REDEFINE, Novo Nordisk). Tirzepatide is an approved medicine — Mounjaro (FDA and EMA, T2D) and Zepbound (FDA, obesity; in the EMA, Mounjaro is also approved in obesity).
No — this is an indirect comparison. The REDEFINE and SURMOUNT/SURPASS programmes differ in their populations, observation periods and methodology. Numerical juxtapositions are methodological approximations.
Both peptides are held in the One Peptides catalogue in the function of research reagents (Research Use Only): Sema+Cagri PEN (blend) or as separate peptides, and GLP-1+GIP PEN for the tirzepatide class. Standards: HPLC ≥98%, MS, COA per batch, cold chain. A full description is given in quality testing and certificates.
CagriSema and tirzepatide are two different answers to the same design question: how to enhance the action of GLP-1 in anti-obesity pharmacology. CagriSema adds a second peptide (cagrilintide, an amylin analogue) — the second axis of action is the amylin receptor in the area postrema. Tirzepatide adds a second receptor (GIPR) within the same molecule.
The regulatory status is fundamentally different: tirzepatide is an approved medicine (Mounjaro, Zepbound). CagriSema remains in phase III REDEFINE. The question of “which acts more strongly” remains without a clinical resolution — there is no head-to-head RCT.
Global disclaimer
All One Peptides products are reagents intended solely for laboratory research use (Research Use Only). Tirzepatide is a medicine approved by the FDA and EMA — its use requires a medical prescription. Semaglutide as a monotherapy is an approved medicine. CagriSema and cagrilintide as a monotherapy are not approved medicines. Numerical juxtapositions of results are an indirect comparison — there is no published head-to-head RCT directly comparing the two molecules.
A research-focused comparison of Melanotan II and PT-141, covering melanocortin receptor selectivity, evidence, safety signals and regulatory status.
A research comparison of MK-677 and ipamorelin, focusing on GHS-R1a signaling, selectivity, administration route, human evidence and WADA status.
We offer a wide selection of peptides tailored to a range of laboratory analytical needs.
Every batch is tested for identity and purity (HPLC, MS) and comes with a certificate of analysis.
We invest in analytical testing and full batch documentation for every product.
Nuestras numerosas reseñas positivas reflejan la satisfacción de nuestros clientes que siguen regresando por más.
¡Suscríbete al boletín!
Obtén un 10% de descuento en tu primera compra
One-Peptides.com
Información
© 2026 ONE-PEPTIDES.COM